Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

NCT05859698 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Schizoaffective Disorder
Bipolar Disorder
Major Depressive Disorder
Tardive Dyskinesia

Interventions

DRUG: Valbenazine

Sponsor

Neurocrine Biosciences